| Popis: |
ObjectiveTo analyze the treatment outcomes for COVID-19 during the early stages of the pandemic at the Mexican Institute of Social Security.Material and MethodsIn this retrospective observational study, we investigated 130,216 patients with COVID-19 treated in two Mexican states during 2020. A competing risk analysis was performed using death and recovery as possible outcomes, followed by a cox-regression and Kaplan-Meier analysis. Additionally, machine learning models were built to predict the outcomes at fixed times.ResultsHigher prevalence of obesity, diabetes, and heart disease comorbidities were found, which is consistent with Mexico’s epidemiological profile. Mortality occurred around 15-20 days from the start of symptoms. Patients undertaking cephalosporin in combination with neuraminidase inhibitors (NAIs) had the worst survival rates, while patients undertaking adamantane, fluoroquinolone, or penicillin had the best survival rates.ConclusionsOur findings recommend against using specific treatment combinations, and should help improve the country’s clinical guidelines. |
